Darbepoetin Administration in Term and Preterm Neonates

Clinics in Perinatology

Volumn 42, Issue 3, 2015, Pages 557-566

  Patel, Shrena ^a   Ohls, Robin K ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Darbepoetin; Erythropoiesis stimulating agents; Neurodevelopment; Neuroprotection; Transfusions

Indexed keywords

ANTIANEMIC AGENT; GROWTH FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; BLOOD TRANSFUSION; CEREBRAL PALSY; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; HEARING IMPAIRMENT; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROLENTAL FIBROPLASIA; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; DRUG ADMINISTRATION; DRUG EFFECTS; INFANT, PREMATURE, DISEASES; NEWBORN; TREATMENT OUTCOME;

DARBEPOETIN ALFA; DRUG ADMINISTRATION SCHEDULE; HEMATINICS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NEUROPROTECTION; TREATMENT OUTCOME;

EID: 84938551632     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2015.04.016     Document Type: Review

References (28)

1. Kirpalani H., Whyte R.K., Andersen C., et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. JPediatr 2006, 149:301-307.
2. McCoy T.E., Conrad A.L., Richman L.C., et al. Neurocognitive profiles of preterm infants randomly assigned to lower or higher hematocrit thresholds for transfusion. Child Neuropsychol 2011, 17:347-367.
3. Whyte R.K., Kirplani H., Aszatalos E.V., et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics 2009, 123:207-213.
4. Stephens B.E., Vohr B.R. Protein intake and neurodevelopmental outcomes. Clin Perinatol 2014, 41:323-329.
5. Juul S. Neuroprotective role of erythropoietin in neonates. JMatern Fetal Neonatal Med 2012, 25(Suppl 4):105-107.
6. Ohlsson A., Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, (3). CD004863.
7. Bishara N., Ohls R.K. Current controversies in the management of the anemia of prematurity. Semin Perinatol 2009, 33:29-34.
8. Widness J.A., Veng-Pedersen P., Peters C., et al. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. JAppl Physiol (1985) 1996, 80:140-148.
9. George J.W., Bracco C.A., Shannon K.M., et al. Age-related differences in erythropoietic response to recombinant human erythropoietin: comparison in adult and infant rhesus monkeys. Pediatr Res 1990, 28:567-571.
10. Ohls R.K., Veerman M.W., Christensen R.D. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition solution. JPediatr 1996, 128:518-523.
11. Ohls R.K., Dai A. Long-acting erythropoietin: clinical studies and potential uses in neonates. Clin Perinatol 2004, 31:77-89.
12. Warwood T.L., Ohls R.K., Wiedmeier S.E., et al. Single-dose darbepoetin administration to anemic preterm neonates. JPerinatol 2005, 25:725-730.
13. Statler P.A., McPherson R.J., Bauer L.A., et al. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 2007, 61:671-675.
14. Traudt C.M., McPherson R.J., Bauer L.A., et al. Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 2013, 35:491-503.
15. Juul S.E., McPherson R.J., Bauer L.A., et al. Aphase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008, 122:383-391.
16. Wu Y.W., Bauer L.A., Ballard R.A., et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012, 130:683-691.
17. Baserga M.C., Beachy J.C., Roberts J.K., et al. DANCE (Darbe Administration in Newborns Undergoing Cooling for Encephalopathy): a safety and pharmacokinetics trial. Pediatr Res 2015, in press.
18. Warwood T.L., Ohls R.K., Lambert D.K., et al. Intravenous administration of darbepoetin to NICU patients. JPerinatol 2006, 26:296-300.
19. Roohi M, Peceny MC, Ohls RK. A randomized, masked, dose response study of darbepoetin administered to preterm infants. In: Programs and abstracts of the Pediatric Academic Society Annual Meeting. Toronto (Ontario), May 5-8, 2007. [abstract: 5899.3].
20. Henry E., Christensen R.D., Sheffield M.J., et al. Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates?. JPerinatol 2015, 35:132-136.
21. Warwood T.L., Lambert D.K., Henry E., et al. Very low birth weight infants qualifying for a 'late' erythrocyte transfusion: does giving darbepoetin along with the transfusion counteract the transfusion's erythropoietic suppression?. JPerinatol 2011, 31:S17-S21.
22. Bierer R., Peceny M.C., Harenberger C.H., et al. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006, 118:e635-e640.
23. Ohls R.K., CHristensen R.D., Kamath-Rayne B.D., et al. Arandomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics 2013, 132:e119-e127.
24. Ohls R.K., Kamath-Rayne B.D., Christensen R.D., et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics 2014, 133:1023-1030.
25. Aher S., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, (3). CD004868.
26. Romagnoli C., Zecca E., Gallini F., et al. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?. Eur J Pediatr 2000, 159:627-628.
27. Messé S.R., McGarvey M.L., Bavaria J.E., et al. Apilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery. Neurocrit Care 2013, 18:75-80.
28. Ehrenreich H., Wessenborn K., Prange H., et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656.